The Role of Estrogen in Ovarian Cancer and the Pathways by Which Estrogen Acts
DOI:
https://doi.org/10.65539/g9h4pg82Keywords:
ovarian cancer, estrogen, estrogen receptors, molecular pathways, targeted therapy, cancer biologyAbstract
Ovarian cancer remains a prevalent and deadly cancer in females. While anti-estrogen therapies have been useful in the treatment of other cancer types, their effectiveness in the treatment of ovarian cancers remains limited due to the limited understanding of estrogen's effects on carcinogenesis and growth promotion in these tissues. This paper aims to summarize the role estrogen plays in ovarian cancer tumorigenesis and its potential value in targeted therapeutics. Estrogen's effects are secondary to interactions with estrogen receptor (ER) α, ER β, and the G protein coupled receptor, GPR30. Genomic signaling of ER-α has been shown to be primarily carcinogenic, while that of ER-β has been shown to be a negative regulator of carcinogenesis. Additionally, ER-α has been found to have carcinogenic effects through non-genomic signaling of the p53, MAPK, EGFR/Her2, PI3K, and IGF/IGFR pathways. GPR30's effects have been found to be more variable and specific to tumor classification. For example, GPR30 is primarily carcinogenic in ovarian epithelial tumor types but appears to have protective effects when highly expressed in granulosa cell tumors. While the above generalizations can be made, a better understanding of estrogen's effects on molecular signaling pathways will potentially allow for development of more effective targeted therapies against ovarian cancer.
Downloads
References
Siegel, R.L., Miller, K.D. and Jemal, A. (2020). Cancer statistics, 2020. CA: a cancer journal for clinicians, 70(1), 7–30. DOI: https://doi.org/10.3322/caac.21590
Ehmann T, Barel S, Xu G, et al. (2019). A comparative analysis of estrogenic pathways between ovarian and cervical cancers. Proceedings of the LECOM Inter-Professional Research Day (Erie, PA), A7.
Orr, B. and Edwards, R.P. (2018). Diagnosis and treatment of ovarian cancer. Hematology/Oncology Clinics, 32(6), 943-964. DOI: https://doi.org/10.1016/j.hoc.2018.07.010
Howlader N, Noone AM, Krapcho M, et al. (2020). SEER Cancer Statistics Review, 1975-2017 [Online]. Available from: https://seer.cancer.gov/archive/csr/1975_2017/. [Accessed Aug 1 2021]
Simpkins, F., Garcia-Soto, A. and Slingerland, J. (2013). New insights on the role of hormonal therapy in ovarian cancer. Steroids, 78(6), 530-537. DOI: https://doi.org/10.1016/j.steroids.2013.01.008
Flouriot, G., Brand, H., Denger, S., et al. (2000). Identification of a new isoform of the human estrogen receptor-alpha (hER-α) that is encoded by distinct transcripts and that is able to repress hER-α activation function 1. The EMBO journal, 19(17), 4688-4700. DOI: https://doi.org/10.1093/emboj/19.17.4688
Shi, L., Dong, B., Li, Z., et al. (2009). Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. Journal of clinical Oncology, 27(21), 3423. DOI: https://doi.org/10.1200/JCO.2008.17.2254
Sieh, W., Köbel, M., Longacre, T.A., et al. (2013). Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. The lancet oncology, 14(9), 853-862. DOI: https://doi.org/10.1016/S1470-2045(13)70323-1
Pujol, P., Rey, J.M., Nirde, P., et al. (1998). Differential expression of estrogen receptor-α and-β messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer research, 58(23), 5367-5373.
O'Donnell, A.J., Macleod, K.G., Burns, D.J., et al. (2005). Estrogen receptor-α mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocrine-related cancer, 12(4), 851-866. DOI: https://doi.org/10.1677/erc.1.01039
Langdon, S.P., Hawkes, M.M., Lawrie, S.S., et al. (1990). Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. British Journal of Cancer, 62(2), 213-216. DOI: https://doi.org/10.1038/bjc.1990.263
Voutsadakis, I.A. (2016). Hormone receptors in serous ovarian carcinoma: prognosis, pathogenesis, and treatment considerations. Clinical Medicine Insights: Oncology, 10, CMO-S32813. DOI: https://doi.org/10.4137/CMO.S32813
Herynk, M.H. and Fuqua, S.A. (2004). Estrogen receptor mutations in human disease. Endocrine reviews, 25(6), 869-898. DOI: https://doi.org/10.1210/er.2003-0010
Bossard, C., Busson, M., Vindrieux, D., et al. (2012). Potential Role of Estrogen Receptor Beta as a Tumor Suppressor of Epithelial Ovarian Cancer. PLoS ONE, 7(9), e44787. DOI: https://doi.org/10.1371/journal.pone.0044787
Treeck, O., Pfeiler, G., Mitter, D., et al. (2007). Estrogen receptor β1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. Journal of Endocrinology, 193(3), 421-433. DOI: https://doi.org/10.1677/JOE-07-0087
Prossnitz, E.R. and Barton, M. (2014). Estrogen biology: new insights into GPER function and clinical opportunities. Molecular and cellular endocrinology, 389(1-2), 71-83. DOI: https://doi.org/10.1016/j.mce.2014.02.002
Albanito, L., Madeo, A., Lappano, R., et al. (2007). G protein–coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer research, 67(4), 1859-1866.
Long, L., Cao, Y. and Tang, L.D. (2012). Transmembrane estrogen receptor GPR30 is more frequently expressed in malignant than benign ovarian endometriotic cysts and correlates with MMP-9 expression. International Journal of Gynecologic Cancer, 22(4). DOI: https://doi.org/10.1097/IGC.0b013e318247323d
Smith, H.O., Arias-Pulido, H., Kuo, D.Y., et al. (2009). GPR30 predicts poor survival for ovarian cancer. Gynecologic oncology, 114(3), 465-471. DOI: https://doi.org/10.1016/j.ygyno.2009.05.015
Heublein, S., Mayr, D., Friese, K., et al. (2014). The G-protein-coupled estrogen receptor (GPER/GPR30) in ovarian granulosa cell tumors. International journal of molecular sciences, 15(9), 15161-15172. DOI: https://doi.org/10.3390/ijms150915161
Kolkova, Z., Casslén, V., Henic, E., et al. (2012). The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer. Journal of ovarian research, 5(1), 1-11. DOI: https://doi.org/10.1186/1757-2215-5-9
Ignatov, T., Modl, S., Thulig, M., et al. (2013). GPER-1 acts as a tumor suppressor in ovarian cancer. Journal of ovarian research, 6(1), 1-10. DOI: https://doi.org/10.1186/1757-2215-6-51
Katzenellenbogen, B.S., (1996). Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biology of reproduction, 54(2), 287-293. DOI: https://doi.org/10.1095/biolreprod54.2.287
O'Malley, B.W. (2005). A life-long search for the molecular pathways of steroid hormone action. Molecular Endocrinology, 19(6), 1402-1411. DOI: https://doi.org/10.1210/me.2004-0480
Weigel, N.L. (1996). Steroid hormone receptors and their regulation by phosphorylation. Biochemical Journal, 319(3), 657-667. DOI: https://doi.org/10.1042/bj3190657
Pietras, R.J. and Márquez-Garbán, D.C. (2007). Membrane-associated estrogen receptor signaling pathways in human cancers. Clinical Cancer Research, 13(16), 4672-4676. DOI: https://doi.org/10.1158/1078-0432.CCR-07-1373
Razandi, M., Pedram, A., Greene, G.L. et al. (1999). Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells. Molecular endocrinology, 13(2), 307-319. DOI: https://doi.org/10.1210/mend.13.2.0239
Bjornstrom, L. and Sjoberg, M. (2005). Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Molecular endocrinology, 19(4), 833-842. DOI: https://doi.org/10.1210/me.2004-0486
Hall, J.M. and Korach, K.S. (2003). Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Molecular Endocrinology, 17(5), 792-803. DOI: https://doi.org/10.1210/me.2002-0438
Webb, P., Nguyen, P., Valentine, C., et al. (1999). The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Molecular Endocrinology, 13(10), 1672-1685. DOI: https://doi.org/10.1210/me.13.10.1672
Anzick, S.L., Kononen, J., Walker, R.L., et al. (1997). AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science, 277(5328), 965-968. DOI: https://doi.org/10.1126/science.277.5328.965
Liang, M. and Zhao, J. (2018). Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis. Eur Rev Med Pharmacol Sci, 22(16), 5134-5139.
Palmieri, C., Gojis, O., Rudraraju, B., et al. (2013). Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. British journal of cancer, 108(10), 2039-2044. DOI: https://doi.org/10.1038/bjc.2013.199
Jakacka, M., Ito, M., Weiss, J, et al. (2001). Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. Journal of Biological Chemistry, 276(17), 13615-13621. DOI: https://doi.org/10.1074/jbc.M008384200
Sasaki, H., Hayakawa, J., Terai, Y., et al. (2008). Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines. Oncogene, 27(19), 2737-2745. DOI: https://doi.org/10.1038/sj.onc.1210926
Hein, S., Mahner, S., Kanowski, C., et al. (2009). Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines. Oncology reports, 22(1), 177-183. DOI: https://doi.org/10.3892/or_00000422
Bardin, A., Moll, F., Margueron, R., et al. (2005). Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology, 146(2), 760-768. DOI: https://doi.org/10.1210/en.2004-1239
Cotran, R., Kumar, V. and Robbins, S. (2015). Pathologic basis of disease. Philadelphia, PA: Saunders Elsevier.
Cho, K.R. and Shih, I.M. (2009). Ovarian cancer. Annual review of pathology: mechanisms of disease, 4, 287-313. DOI: https://doi.org/10.1146/annurev.pathol.4.110807.092246
Berger, C.E., Qian, Y., Liu, G., et al. (2012). p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells. Journal of Biological Chemistry, 287(36), 30117-30127. DOI: https://doi.org/10.1074/jbc.M112.367326
Qin, C., Nguyen, T., Stewart, J., et al. (2002). Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor κB/CCAAT-binding transcription factor-1 complex. Molecular Endocrinology, 16(8), 1793-1809. DOI: https://doi.org/10.1210/me.2002-0006
Wright, J.W., Stouffer, R.L. and Rodland, K.D. (2005). High-dose estrogen and clinical selective estrogen receptor modulators induce growth arrest, p21, and p53 in primate ovarian surface epithelial cells. The Journal of Clinical Endocrinology & Metabolism, 90(6), 3688-3695. DOI: https://doi.org/10.1210/jc.2004-2456
Guan, X., Zhang, N., Yin, Y., et al. (2012). Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables. Journal of Experimental & Clinical Cancer Research, 31(1), 1-8. DOI: https://doi.org/10.1186/1756-9966-31-89
Sayeed, A., Konduri, S.D., Liu, W., et al. (2007). Estrogen receptor α inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer research, 67(16), 7746-7755. DOI: https://doi.org/10.1158/0008-5472.CAN-06-3724
Bailey, S.T., Shin, H., Westerling, T., et al. (2012). Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proceedings of the National Academy of Sciences, 109(44), 18060-18065. DOI: https://doi.org/10.1073/pnas.1018858109
Berger, C., Qian, Y. and Chen, X. (2013). The p53-estrogen receptor loop in cancer. Current molecular medicine, 13(8), 1229-1240. DOI: https://doi.org/10.2174/15665240113139990065
Ren, Y.A., Mullany, L.K., Liu, Z., et al. (2016). Mutant p53 promotes epithelial ovarian cancer by regulating tumor differentiation, metastasis, and responsiveness to steroid hormones. Cancer research, 76(8), 2206-2218. DOI: https://doi.org/10.1158/0008-5472.CAN-15-1046
Mullany, L.K., Liu, Z., Wong, K.K., et al. (2014). Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases. Molecular Endocrinology, 28(1), 127-137. DOI: https://doi.org/10.1210/me.2013-1308
Rosen, D.G., Yang, G., Liu, G., et al. (2009). Ovarian cancer: pathology, biology, and disease models. Frontiers in bioscience: a journal and virtual library, 14, 2089. DOI: https://doi.org/10.2741/3364
Ho, C.L., Kurman, R.J., Dehari, R., et al. (2004). Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer research, 64(19), 6915-6918. DOI: https://doi.org/10.1158/0008-5472.CAN-04-2067
Lu, L., Wang, J., Wu, Y., et al. (2016). Rap1A promotes ovarian cancer metastasis via activation of ERK/p38 and notch signaling. Cancer medicine, 5(12), 3544-3554. DOI: https://doi.org/10.1002/cam4.946
Hew, K.E., Miller, P.C., El-Ashry, D., et al. (2016). MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in ER-positive high-grade serous ovarian cancer. Clinical Cancer Research, 22(4), 935-947. DOI: https://doi.org/10.1158/1078-0432.CCR-15-0534
Zhang, L.Q., Lv, R.W., Qu, X.D., et al. (2017). Aloesin suppresses cell growth and metastasis in ovarian cancer SKOV3 cells through the inhibition of the MAPK signaling pathway. Analytical Cellular Pathology, 2017, 8158254. DOI: https://doi.org/10.1155/2017/8158254
Lim, W. and Song, G. (2017). Inhibitory effects of delphinidin on the proliferation of ovarian cancer cells via PI3K/AKT and ERK 1/2 MAPK signal transduction. Oncology Letters, 14(1), 810-818. DOI: https://doi.org/10.3892/ol.2017.6232
Simpkins, F., Hevia-Paez, P., Sun, J., et al. (2012). Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clinical cancer research, 18(21), 5911-5923. DOI: https://doi.org/10.1158/1078-0432.CCR-12-1257
Chung, Y.L., Sheu, M.L., Yang, S.C., et al. (2002). Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. International journal of cancer, 97(3), 306-312. DOI: https://doi.org/10.1002/ijc.1614
Arpino, G., Wiechmann, L., Osborne, C.K. et al. (2008). Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrine reviews, 29(2), 217-233. DOI: https://doi.org/10.1210/er.2006-0045
Osborne, C.K., Bardou, V., Hopp, T.A., et al. (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute, 95(5), 353-361. DOI: https://doi.org/10.1093/jnci/95.5.353
Mullen, P., Cameron, D.A., Hasmann, M., et al. (2007). Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Molecular cancer therapeutics, 6(1), 93-100. DOI: https://doi.org/10.1158/1535-7163.MCT-06-0401
Ranjbar, R., Nejatollahi, F., Ahmadi, A.S.N., et al. (2015). Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) in patients with serous ovarian carcinoma and their clinical significance. Iranian journal of cancer prevention, 8(4). DOI: https://doi.org/10.17795/ijcp-3428
Psyrri, A., Kassar, M., Yu, Z., et al. (2005). Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clinical Cancer Research, 11(24), 8637-8643. DOI: https://doi.org/10.1158/1078-0432.CCR-05-1436
Tanaka, Y., Terai, Y., Tanabe, A., et al. (2011). Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer biology & therapy, 11(1), 50-57. DOI: https://doi.org/10.4161/cbt.11.1.13877
Altomare, D.A., Wang, H.Q., Skele, K.L., et al. (2004). AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene, 23(34), 5853-5857. DOI: https://doi.org/10.1038/sj.onc.1207721
Cheaib, B., Auguste, A. and Leary, A. (2015). The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chinese journal of cancer, 34(1), 4-16. DOI: https://doi.org/10.5732/cjc.014.10289
Hua, K., Feng, W., Cao, Q., et al. (2008). Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. International journal of oncology, 33(5), 959-967.
Lu, Z., Zhang, Y., Yan, X., et al. (2014). Estrogen stimulates the invasion of ovarian cancer cells via activation of the PI3K/AKT pathway and regulation of its downstream targets E-cadherin and α-actinin-4. Molecular Medicine Reports, 10(5), 2433-2440. DOI: https://doi.org/10.3892/mmr.2014.2561
Hua, K., Din, J., Cao, Q., et al. (2009). Estrogen and progestin regulate HIF-1α expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway. Oncology reports, 21(4), 893-898. DOI: https://doi.org/10.3892/or_00000300
Beauchamp, M.C., Yasmeen, A., Knafo, A. et al. (2010). Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. Journal of oncology, 2010, 257058. DOI: https://doi.org/10.1155/2010/257058
Foulstone, E., Prince, S., Zaccheo, O., et al. (2005). Insulin‐like growth factor ligands, receptors, and binding proteins in cancer. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 205(2), 145-153. DOI: https://doi.org/10.1002/path.1712
Walker, G., MacLeod, K., Williams, A.R., et al. (2007). Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clinical Cancer Research, 13(5), 1438-1444. DOI: https://doi.org/10.1158/1078-0432.CCR-06-2245
Flyvbjerg, A., Mogensen, O., Mogensen, B., et al. (1997). Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. The Journal of Clinical Endocrinology & Metabolism, 82(7), 2308-2313. DOI: https://doi.org/10.1210/jc.82.7.2308
Lu, L., Katsaros, D., Wiley, A., et al. (2006). The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clinical Cancer Research, 12(4), 1208-1214. DOI: https://doi.org/10.1158/1078-0432.CCR-05-1801
Kahlert, S., Nuedling, S., Van Eickels, M., et al. (2000). Estrogen receptor α rapidly activates the IGF-1 receptor pathway. Journal of Biological Chemistry, 275(24), 18447-18453. DOI: https://doi.org/10.1074/jbc.M910345199
Chen, J., Zhao, K.N., Li, R., et al. (2014). Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer. Current medicinal chemistry, 21(26), 3070-3080. DOI: https://doi.org/10.2174/0929867321666140414095605
Fukushima, T., Nakamura, Y., Yamanaka, D., et al. (2012). Phosphatidylinositol 3-kinase (PI3K) activity bound to insulin-like growth factor-I (IGF-I) receptor, which is continuously sustained by IGF-I stimulation, is required for IGF-I-induced cell proliferation. Journal of Biological Chemistry, 287(35), 29713-29721. DOI: https://doi.org/10.1074/jbc.M112.393074
Cao, Z., Liu, L.Z., Dixon, D.A., et al. (2007). Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cellular signalling, 19(7), 1542-1553. DOI: https://doi.org/10.1016/j.cellsig.2007.01.028
Qian, H., Xuan, J., Liu, Y. et al. (2016). Function of G-protein-coupled estrogen receptor-1 in reproductive system tumors. Journal of immunology research, 2016, 7128702. DOI: https://doi.org/10.1155/2016/7128702
Revankar, C.M., Cimino, D.F., Sklar, L.A., et al. (2005). A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 307(5715), 1625-1630. DOI: https://doi.org/10.1126/science.1106943
Albanito, L., Madeo, A., Lappano, R., et al. (2007). G protein–coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer research, 67(4), 1859-1866. DOI: https://doi.org/10.1158/0008-5472.CAN-06-2909
Fujiwara, S., Terai, Y., Kawaguchi, H., et al. (2012). GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer. Journal of ovarian research, 5(1), 1-10. DOI: https://doi.org/10.1186/1757-2215-5-35
François, C.M., Wargnier, R., Petit, F., et al. (2015). 17β-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1. Carcinogenesis, 36(5), 564-573. DOI: https://doi.org/10.1093/carcin/bgv041
Schüler-Toprak, S., Weber, F., Skrzypczak, M., et al. (2018). Estrogen receptor β is associated with expression of cancer associated genes and survival in ovarian cancer. BMc cancer, 18(1), 1-9. DOI: https://doi.org/10.1186/s12885-018-4898-0
Bookman, M.A., Darcy, K.M., Clarke-Pearson, D., et al. (2003). Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. Journal of clinical oncology, 21(2), 283-290. DOI: https://doi.org/10.1200/JCO.2003.10.104
Thouvenin, L., Charrier, M., Clement, S., et al. (2021). Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab. Gynecologic Oncology Reports, 37, 100787. DOI: https://doi.org/10.1016/j.gore.2021.100787
Lorusso, D., Hilpert, F., Martin, A.G., et al. (2019). Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. International Journal of Gynecologic Cancer, 29(7). DOI: https://doi.org/10.1136/ijgc-2019-000370
Chelariu-Raicu, A., Levenback, C.F., Slomovitz, B.M., et al. (2020). Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. International Journal of Gynecologic Cancer, 30(11). DOI: https://doi.org/10.1136/ijgc-2020-001863
Schilder, R.J., Pathak, H.B., Lokshin, A.E., et al. (2009). Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecologic oncology, 113(1), 21-27. DOI: https://doi.org/10.1016/j.ygyno.2008.12.003
Gershenson, D.M., Miller, A., Brady, W.E., et al. (2022). Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. The Lancet, 399(10324), 541-553. DOI: https://doi.org/10.1016/S0140-6736(21)02175-9
He, Y., Alejo, S., Venkata, P.P., Johnson, J.D., Loeffel, I., Pratap, U.P., Zou, Y., Lai, Z., Tekmal, R.R., Kost, E.R. and Sareddy, G.R. (2022). Therapeutic targeting of ovarian Cancer stem cells using estrogen receptor Beta agonist. International journal of molecular sciences, 23(13), 7159. DOI: https://doi.org/10.3390/ijms23137159
Banerjee, A., Cai, S., Xie, G., Li, N., Bai, X., Lavudi, K., Wang, K., Zhang, X., Zhang, J., Patnaik, S. and Backes, F.J. (2022). A Novel Estrogen Receptor β Agonist Diminishes Ovarian Cancer Stem Cells via Suppressing the Epithelial-to-Mesenchymal Transition. Cancers, 14(9), 2311. DOI: https://doi.org/10.3390/cancers14092311
Published
Issue
Section
License
Copyright (c) 2023 Timothy Ehmann, Stephanie Barel, Amitabha Ray, Daniel Borsch (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
